Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2020-07-01
Schriftenreihe:	Endocrinology, Diabetes & Metabolism
Schlagworte:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
Online-Zugang:	https://doi.org/10.1002/edm2.159
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!